6 recruiting, 2 active not recruiting, 2 completed, 2 not yet recruiting. 7 Phase 2, 3 Phase 4, 2 Phase 3, 1 Not applicable, 1 Phase 1.
Follow pralsetinib: new trials by email Literature Review of pralsetinib trials Research Report on pralsetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC Pralsetinib, Leucogen - Non-small Cell Lung Cancer, RET Fusion | Not applicable | Not yet recruiting | Fudan University | 25 | 2026-02-05 | 2026-02-18 |
| Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor - Thyroid Cancer, Thyroid Neoplasms | Recruiting | Fujian Medical University | 120 | 2025-12-23 | 2026-02-19 | |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Sunvozertinib, Crizotinib, Pralsetinib - Lung Cancer Stage III, Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 120 | 2024-11-01 | 2026-04-21 |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II Alectinib, Atezolizumab, Erlotinib - Solid Tumor, Advanced Solid Tumor | Active not recruiting | Seoul National University Bundang Hospital | 1000 | 2022-09-28 | 2026-09-30 | |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Genentech, Inc. | 99 | 2020-11-06 | 2026-10-13 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | Hoffmann-La Roche | 223 | 2020-07-24 | 2026-03-05 |
| A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy - Advanced Thyroid Cancer Patients Who Received Target Therapy | Phase 4 | Recruiting | Fudan University | 800 | 2020-01-01 | 2025-08-14 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC pralsetinib (BLU-667) - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Approved for marketing | Blueprint Medicines Corporation | 2021-08-13 |
Carcinoma, Non-Small-Cell Lung (8) · Thyroid Neoplasms (4) · Carcinoma, Medullary (3) · Lung Neoplasms (3) · Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2)
Hoffmann-La Roche (4) · Fudan University (2) · Fujian Medical University (2) · Genentech, Inc. (2) · Blueprint Medicines Corporation (1) · Fondazione per la Medicina Personalizzata (1) · Rigel Pharmaceuticals (1) · Seoul National University Bundang Hospital (1) · Sun Yat-sen University (1) · West China Hospital (1)
China (7) · Spain (5) · Italy (4) · South Korea (4) · United States (4) · Belgium (3) · France (3) · Germany (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Hong Kong (2) · Japan (2) · Netherlands (2) · Poland (2)
Andrea Botticelli (1) · Dongmei Ji, M.D (1) · Paolo Marchetti (1) · Qinghai Ji, M.D (1) · Si-Yu Wang, MD (1) · Yansong Lin, M.D (1) · Yu Wang, M.D (1) · Zhihui Li, Professor (1)
PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 38724991, PMID 40086048, PMID 40304938, PMID 40639400, PMID 41023484, PMID 41213248, PMID 41392942, PMID 41886723, PMID 41963505
2023 (2), 2016 (1), 2018 (1), 2019 (1)